Blood Pressure Status Modulates the Therapeutic Response to Sodium‐Glucose Cotransporter 2 Inhibitors in Diabetic Macular Edema: A Post Hoc Subgroup Analysis of the COMET Trial

Documents similaires

• Sodium–glucose cotransporter 2 inhibition and injection burden in mild diabetic macular edema: An exploratory post hoc analysis of the COMET trial
  par: Yoko Takatsuna, et autres
  Publié: (2026)
• Ophthalmic Backgrounds Influencing the Efficacy of SGLT2 Inhibitor in Diabetic Macular Oedema: Post‐hoc Analysis of the COMET Trial
  par: Ryoichi Ishibashi, et autres
  Publié: (2026)
• Sodium‐glucose co‐transporter 2 inhibitors reduce the intravitreal anti‐ VEGF treatment necessity in eyes with early diabetic macular oedema: A post‐hoc analysis focusing on the fellow eye of the COMET trial
  par: Tomoaki Tatsumi, et autres
  Publié: (2025)
• Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: Sub‐analysis of a randomized controlled study
  par: Kiichi Hirayama, et autres
  Publié: (2025)
• Sodium‐Glucose Cotransporter 2 Inhibitors for Mesenchymal–Epithelial Transition Inhibitor‐Induced Edema
  par: Takuya Oyakawa, et autres
  Publié: (2024)